Analyst Ratings For Gemphire Therapeutics (NASDAQ:GEMP)
Today, Jefferies Group LLC raised its price target on Gemphire Therapeutics (NASDAQ:GEMP) to per share.
There are 5 buy ratings on the stock.
The current consensus rating on Gemphire Therapeutics (NASDAQ:GEMP) is Buy (Score: 3.00) with a consensus target price of $27.60 per share, a potential 41.32% upside.
Some recent analyst ratings include
- 4/10/2017-Piper Jaffray Companies initiated coverage with a Overweight rating.
- 9/16/2016-Royal Bank Of Canada Reiterated Rating of Outperform.
- 9/6/2016-Laidlaw initiated coverage with a Buy rating.
- On 3/10/2017 Andy Sassine, Director, bought 21,119 with an average share price of $9.47 per share and the total transaction amounting to $199,996.93. View SEC Filing
- On 8/10/2016 David Lowenschuss, Insider, bought 11,120 with an average share price of $10.00 per share and the total transaction amounting to $111,200.00. View SEC Filing
- On 8/10/2016 Jeffrey S Mathiesen, CFO, bought 4,000 with an average share price of $10.00 per share and the total transaction amounting to $40,000.00. View SEC Filing
- On 8/10/2016 Mina Sooch, CEO, bought 52,500 with an average share price of $10.00 per share and the total transaction amounting to $525,000.00. View SEC Filing
- On 8/10/2016 Steven R Ph.D. Gullans, Director, bought 500,000 with an average share price of $10.00 per share and the total transaction amounting to $5,000,000.00. View SEC Filing
Recent Trading Activity for Gemphire Therapeutics (NASDAQ:GEMP)
Shares of Gemphire Therapeutics closed the previous trading session at 19.53 down -1.54 -7.31% with 75,461 shares trading hands.